Who is sponsoring NCT01128322?

NCT01128322 is sponsored by Chong Kun Dang Pharmaceutical.

What condition does NCT01128322 study?

NCT01128322 studies Hypertension.

What drugs are being tested in NCT01128322?

Interventions: S-Amlodipine, Telmisartan, S-Amlodipine, Telmisartan, Placebo.

What is the status of NCT01128322?

NCT01128322 is currently COMPLETED.

Last reviewed 2011-04-22 · How we verify

A Randomized, Double-blind, Multi-center, Multi-factorial, Phase 2 Trial to Evaluate the Efficacy and Safety of S-Amlodipine/Telmisartan Combined or Alone and Select Better Dose of CKD-828 in Patients With Essential Hypertension

NCT01128322 Phase 2 COMPLETED

The aim of this trial is to determine the best dose combination of S-Amlodipine and Telmisartan as compared to monotherapy by assessing the blood pressure lowering effects of a once daily regimen of various combinations of S-Amlodipine and Telmisartan, compared to their monotherapy components and placebo, in patients with stage I or II essential hypertension(a mean seated cuff diastolic blood pressure \>=95 and \<=115 mmHg).

Details

Lead sponsor	Chong Kun Dang Pharmaceutical
Phase	Phase 2
Status	COMPLETED
Enrolment	430
Start date	2010-07
Completion	2011-03

Conditions

Hypertension

Interventions

S-Amlodipine, Telmisartan
S-Amlodipine
Telmisartan
Placebo

Primary outcomes

Mean Sitting Diastolic Blood Pressure(MSDBP) — After 8 weeks of treatment

Countries

South Korea